Skip to main content

Table 3 Comparison of clinical response between ANA titer ≤ 1:80 and ≥ 1:160

From: Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study

 

ANA titer

 

Before IFX

After IFX

EULAR

≤ 1:80

≥ 1:160

P valuea

≤ 1:80

≥ 1:160

P valuea

response

(n = 79)

(n = 27)

 

(n = 56)

(n = 38)

 

Good

66%

26%

< 0.001

77%

11%

< 0.001

(remission)

(16%)

(7%)

< 0.001

(59%)

(3%)

< 0.001

Moderate

9%

33%

< 0.001

7%

29%

< 0.001

No

25%

41%

< 0.001

16%

60%

< 0.001

  1. ANA, antinuclear antibodies; IFX, infliximab; aAnalyzed with a χ2 test.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us